Full Product Name
VHL siRNA (Mouse)
Product Synonym Names
VHLH; Von Hippel-Lindau disease tumor suppressor; pVHL
Product Gene Name
VHL sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P40338
Specificity
VHL siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse VHL gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of VHL sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
VHL sirna
siRNA to inhibit VHL expression using RNA interference
Applications Tested/Suitable for VHL sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for VHL. It may not necessarily be applicable to this product.
NCBI Accession #
NP_033533.1
[Other Products]
NCBI GenBank Nucleotide #
NM_009507.3
[Other Products]
UniProt Primary Accession #
P40338
[Other Products]
UniProt Related Accession #
P40338[Other Products]
Molecular Weight
20,770 Da
NCBI Official Full Name
von Hippel-Lindau disease tumor suppressor
NCBI Official Synonym Full Names
von Hippel-Lindau tumor suppressor
NCBI Official Symbol
Vhl [Similar Products]
NCBI Official Synonym Symbols
Vhlh
[Similar Products]
NCBI Protein Information
von Hippel-Lindau disease tumor suppressor
UniProt Protein Name
Von Hippel-Lindau disease tumor suppressor
UniProt Synonym Protein Names
pVHL
Protein Family
Von Hippel-Lindau disease tumor suppressor
UniProt Gene Name
Vhl [Similar Products]
UniProt Synonym Gene Names
Vhlh [Similar Products]
UniProt Entry Name
VHL_MOUSE
UniProt Comments for VHL
VHL: Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia- inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2. Component of the VCB (VHL-Elongin BC-CUL2) complex; this complex acts as a ubiquitin-ligase E3 and directs proteasome- dependent degradation of targeted proteins. Interacts with CUL2; this interaction is dependent on the integrity of the trimeric VBC complex. Interacts (via the beta domain) with HIF1A (via the NTAD domain); this interaction mediates degradation of HIF1A in normoxia and, in hypoxia, prevents ubiqitination and degradation of HIF1A by mediating hypoxia-induced translocation to the nucleus, a process which requires a hypoxia-dependent regulatory signal. Interacts with ADRB2; the interaction, in normoxia, is dependent on hydroxylation of ADRB2 and the subsequent VCB- mediated ubiquitination and degradation of ADRB2. Under hypoxia, hydroxylation, interaction with VHL, ubiquitination and subsequent degradation of ADRB2 are dramatically decreased. Interacts with RNF139, USP33 and PHF17. Found in a complex composed of LIMD1, VHL, EGLN1/PHD2, TCEB2 AND CUL2. Isoform 1 and isoform 3 interact with LIMD1 (via LIM zinc-binding 2), AJUBA (via LIM domains) and WTIP (via LIM domains). Interacts with EPAS1. Expressed in the ***** and fetal brain and kidney. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Ubiquitin ligase; Tumor suppressor
Cellular Component: Cul2-RING ubiquitin ligase complex; nucleoplasm; intermediate filament cytoskeleton; mitochondrion; membrane; cell; VCB complex; cytoplasm; nucleolus; intracellular; cytosol; nucleus; cilium
Molecular Function: protein binding; enzyme binding; protein complex binding; transcription factor binding
Biological Process: neuron differentiation; proteasomal protein catabolic process; protein transport; extracellular matrix organization and biogenesis; blood vessel endothelial cell migration; regulation of transcription, DNA-dependent; protein heterooligomerization; positive regulation of transcription, DNA-dependent; regulation of catecholamine metabolic process; response to hypoxia; protein ubiquitination; protein catabolic process; NLS-bearing substrate import into nucleus; angiogenesis; negative regulation of transcription from RNA polymerase II promoter
Research Articles on VHL
1. Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
